BioCryst Pharmaceuticals, Inc.

564 articles about BioCryst Pharmaceuticals, Inc.

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2023

  5/4/2023

  BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees stock options to purchase an aggregate of 34,000 shares, and restricted stock units covering an aggregate of 23,800 shares, of BioCryst common stock.

• BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update

  5/3/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

• BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat)

  4/27/2023

  BioCryst Pharmaceuticals, Inc. announced new data from the APeX-S clinical trial, which evaluated oral, once-daily ORLADEYO® for the prophylactic treatment of hereditary angioedema, showing sustained reduction in disease burden for patients across multiple subgroups through 96 weeks of treatment.

• BioCryst to Report First Quarter 2023 Financial Results on May 3

  4/19/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2023 financial results on Wednesday, May 3, 2023.

• BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon

  4/18/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has secured $450 million in committed financing from funds managed by Pharmakon Advisors, LP. BioCryst has elected to draw $300 million of the $450 million available to the company on the closing date.

• BioCryst to Present at Upcoming Investor Conferences - April 12, 2023

  4/12/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following investor conferences.

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 04, 2023

  4/4/2023

  BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees stock options to purchase an aggregate of 124,300 shares, and restricted stock units covering an aggregate of 40,350 shares, of BioCryst common stock.

• BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

  3/31/2023

  BioCryst Pharmaceuticals, Inc. announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately.

• BioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success

  3/29/2023

  BioCryst Pharmaceuticals, Inc. acknowledged the many contributions of Robert A. Ingram, the company’s chairman of the board, who recently passed away.

• CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada

  3/8/2023

  BioCryst Pharmaceuticals, Inc. announced that the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee has issued a positive recommendation for ORLADEYO® to be reimbursed for the routine prevention of attacks of hereditary angioedema in adults and pediatric patients 12 years of age and older.

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2023

  3/2/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 110,400 shares, and restricted stock units (RSUs) covering an aggregate of 51,300 shares, of BioCryst common stock.

• BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)

  2/24/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data from the APeX-S and APeX-2 clinical trials which evaluated oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE).

• BioCryst to Present at Upcoming Investor Conferences - February 22, 2023

  2/22/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Cowen 43rd Annual Health Care Conference in Boston, MA on Wednesday, March 8th at 12:50 p.m. ET and the Barclays 2023 Global Healthcare Conference in Miami, FL on Tuesday, March 14th at 9:30 a.m. ET.

• BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones

  2/21/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.

• BioCryst to Report Fourth Quarter 2022 Financial Results on February 21

  2/7/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2022 financial results on Tuesday, February 21, 2023.

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 6, 2023

  2/6/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 20 newly-hired employees stock options to purchase an aggregate of 287,200 shares, and restricted stock units (RSUs) covering an aggregate of 101,700 shares, of BioCryst common stock.

• BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

  2/3/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts featuring data on oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held in San Antonio, Texas, from February 24-27, 2023.

• BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

  1/26/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the pivotal APeX-P trial evaluating oral, once-daily ORLADEYO ® (berotralstat) in pediatric hereditary angioedema (HAE) patients who are 2 to12 years of age.

• BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

  1/23/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO ® (berotralstat) in Central and Eastern Europe (CEE).

• BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

  1/9/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that initial data from ongoing phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trials in healthy volunteers show rapid, sustained and >97 percent suppression of the alternative pathway (AP) of the complement system 24 hours following a single 110 mg dose.